-- Neurologix Files to Liquidate Under Chapter 7 Bankruptcy
-- B y   D a w n   M c C a r t y
-- 2012-03-16T16:58:18Z
-- http://www.bloomberg.com/news/2012-03-16/neurologix-files-to-liquidate-under-chapter-7-bankruptcy-1-.html
Neurologix Inc. (NRGX) , a clinical-stage
developer of gene therapies for disorders of the brain and
central nervous system, filed for protection under the
liquidation provision of the U.S. Bankruptcy Code.  The Fort Lee, New Jersey-based company listed assets of
$1.2 million and debt of $12.9 million as of March 6 in Chapter
7 documents filed today in  U.S. Bankruptcy Court  in Wilmington,
Delaware. Chapter 7 proceedings let companies liquidate their
assets while being protected from creditors.  Current company programs address conditions such as
Parkinson’s disease, epilepsy, depression and  Huntington’s
disease , according to its  website .  In February, Neurologix hired Global Resource Partners Inc.
to provide consulting and financial advice after Chief Financial
Officer Marc Panoff resigned.  The company is owned by Corriente Advisors LLC, with a
23 percent stake; General Electric Pension Trust, with
20.12 percent; Palisades Private Partnership LP, with
12.1 percent; DaimlerChrysler Corp. LLC Master Retirement Trust,
with 7.08 percent; and ATEC Trust with 6.16 percent, according
to court papers.  The case is In re Neurologix Inc., 12-10936, U.S.
Bankruptcy Court, District of Delaware (Wilmington).  To contact the reporter on this story:
Dawn McCarty in Wilmington at 
 dmccarty@bloomberg.net   To contact the editor responsible for this story:
 John Pickering  at   jpickering@bloomberg.net . 